This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|November 14, 2013
Eli Lilly Plans Insulin Manufacturing Investments
Author(s)BioPharm International Editors
Ei Lilly announces investments in insulin manufacturing capacity for its sites in Indianapolis, Puerto Rico, France, and China.
Advertisement
Nearly half of the $1-billion investment will improve the company's Indianapolis sites, where Eli Lilly has been manufacturing insulin since it introduced the first commercially available insulin product in 1923. The new manufacturing investments will support existing and future insulin-based medicines. In France, the company is investing $120 million to enhance insulin-cartridge manufacturing capacity. At its sites in Indianapolis and Puerto Rico, the company is investing $245 million to expand insulin active- ingredient and delivery-device manufacturing capacity. In addition, the company will invest $350 million to expand insulin-cartridge manufacturing capacity in China.
In addition to these new investments, Eli Lilly recently reported other insulin-related commitments in Indianapolis totaling $320 million to expand insulin active-ingredient and drug-product manufacturing capacity as well as an additional $80 million in ancillary projects. Together, this brings the company's total investment commitment during the past year to more than $1 billion, which will be invested during the next several years.
The commitment to expand insulin production in China is the latest in a series of diabetes-related investments, such as the opening of the Lilly China Research and Development Center in Shanghai last year. The company is also investing in diabetes research. The company currently has 14 new molecular entities in clinical development, including three under regulatory review and another in Phase III, for the treatment of diabetes and related complications.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5